RNUG.F Stock Overview
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
ReNeuron Group plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.043 |
52 Week High | UK£0.092 |
52 Week Low | UK£0.039 |
Beta | 0.69 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -97.83% |
5 Year Change | -98.67% |
Change since IPO | -90.56% |
Recent News & Updates
Recent updates
Shareholder Returns
RNUG.F | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | -4.3% | -0.8% |
1Y | n/a | 3.9% | 25.9% |
Return vs Industry: Insufficient data to determine how RNUG.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how RNUG.F performed against the US Market.
Price Volatility
RNUG.F volatility | |
---|---|
RNUG.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 12.0% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RNUG.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RNUG.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 26 | n/a | https://www.reneuron.com |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells.
ReNeuron Group plc Fundamentals Summary
RNUG.F fundamental statistics | |
---|---|
Market cap | US$2.44m |
Earnings (TTM) | -US$6.41m |
Revenue (TTM) | US$314.60k |
7.7x
P/S Ratio-0.4x
P/E RatioIs RNUG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RNUG.F income statement (TTM) | |
---|---|
Revenue | UK£249.00k |
Cost of Revenue | UK£3.65m |
Gross Profit | -UK£3.40m |
Other Expenses | UK£1.67m |
Earnings | -UK£5.07m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.089 |
Gross Margin | -1,367.47% |
Net Profit Margin | -2,037.35% |
Debt/Equity Ratio | 0% |
How did RNUG.F perform over the long term?
See historical performance and comparison